Publications & Posters
Scholary publications
Spinal Muscular Atrophy
Apitegromab
July 2019
SLAS Discovery
A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation
Immuno-Oncology
SRK-181
April 2019
American Association for Cancer Research (AACR) Annual Meeting
Defeating primary checkpoint resistance: SRK-181 is a first-in-class, fully human antibody that renders resistant tumors sensitive to anti-PD-1
Spinal Muscular Atrophy
Apitegromab
April 2019
Human Molecular Genetics
Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy
Immuno-Oncology
SRK-181
November 2018
The Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Defeating checkpoint resistance: Highly specific inhibition of latent TGFβ1 activation renders resistant solid tumors vulnerable to PD-1 blockade
Anemia
SRK-256
October 2018
12th International BMP Conference
RGMc-selective antibodies modulate iron homeostasis in vivo
March 2018
Gordon Research Conference
